Top

Cancer Immunology, Immunotherapy

Published in:

07-08-2022 | Bevacizumab | Original Article

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Authors: Yu Feng, Le Tang, Hongyu Wang, Yutao Liu, Sheng Yang, Lin Lin, Xingsheng Hu, Yuankai Shi

Published in: Cancer Immunology, Immunotherapy | Issue 2/2023

Abstract

Background

To report the efficacy and safety data of immunotherapy plus angiogenic inhibitors treatment in lung adenocarcinoma patients.

Methods

Eligible patients with pathological or cytological confirmed locally advanced or metastatic lung adenocarcinoma and treated with immune checkpoint inhibitors (ICI) plus angiogenic inhibitors were enrolled. The primary endpoints were progressive free survival (PFS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.

Results

A total of 46 consecutive enrolled patients received ICI plus angiogenic inhibitor, and the median follow-up was 9.6 months (range 1.5–32.5). The ORR and DCR were 8.7% (n = 4) and 50% (n = 23), respectively. Median PFS and OS were 2.9 months (95% CI 2.1–3.7) and 12.3 months (95% CI 7.6–17.0), respectively. Patients at stage IVB had an inferior PFS than stage IIIC or IVA (2.8 months vs 4.4 months, P = 0.003). The median PFS of patients who were treated with ICI plus bevacizumab was shorter than ICI plus anlotinib or apatinib (1.2 months vs 3.3 months, P = 0.005). The occurrence of hypertension during the combination treatment has been related to a tendency for prolonged PFS (5.5 months vs 2.6 months; P = 0.05). The overall incidence of treatment-related adverse events (TRAE) was 89.1% (n = 41), and grade 3–4 TRAE was occupied 21.4% (n = 10).

Conclusion

This study objectively demonstrated that the treatment of ICI and antiangiogenic agents in lung adenocarcinoma could be a promising alternative therapeutic regimen, and the toxic effects were manageable. Subgroup analysis revealed that small molecular angiogenic inhibitors plus ICI and low tumor burden during treatment were better prognostic factors.

Sharma SV, Bell DW, Settleman J (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181. https://doi.org/10.1038/nrc2088CrossRef

Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. https://doi.org/10.1038/nature05945CrossRef

Drilon A, Jenkins C, Iyer S et al (2021) ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol 18(1):35–55. https://doi.org/10.1038/s41571-020-0408-9CrossRef

Chiosea SI, Sherer CK, Jelic T et al (2011) KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol 24(12):1571–1577. https://doi.org/10.1038/modpathol.2011.109CrossRef

Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367CrossRef

Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange; Promotion Association for Medical and Healthcare (2021) Clinical practice guideline for stage IV primary lung cancer in China (2021 version). Zhonghua zhong liu za zhi [Chin J Oncol] 43:39–59. https://doi.org/10.3760/cma.j.cn112152-20201009-00884CrossRef

Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824CrossRef

Almutairi AR, Alkhatib N, Martin J et al (2019) Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol 142:16–25. https://doi.org/10.1016/j.critrevonc.2019.07.004CrossRef

Zhao S, Ren S, Jiang T et al (2019) Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res 7(4):630–643. https://doi.org/10.1158/2326-6066.CIR-17-0640CrossRef

10.

Herbst RS, Arkenau HT, Santana-Davila R et al (2019) Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol 20(8):1109–1123. https://doi.org/10.1016/S1470-2045(19)30458-9CrossRef

11.

Chu T, Zhong R, Zhong H et al (2021) Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol 16(4):643–652. https://doi.org/10.1016/j.jtho.2020.11.026CrossRef

12.

Zhou C, Wang Y, Zhao J et al (2021) Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res 27(5):1296–1304. https://doi.org/10.1158/1078-0432.CCR-20-3136CrossRef

13.

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer–immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349CrossRef

14.

Shi Y, Au JS, Thongprasert S et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154–162. https://doi.org/10.1097/JTO.0000000000000033CrossRef

15.

Shi Y, Li J, Zhang S et al (2015) Molecular epidemiology of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland china subset analysis of the PIONEER study. PLoS ONE 10(11):e0143515. https://doi.org/10.1371/journal.pone.0143515CrossRef

16.

Wu YL, Lu S, Cheng Y et al (2019) Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 14(5):867–875. https://doi.org/10.1016/j.jtho.2019.01.006CrossRef

17.

Wu DW, Huang HY, Tang Y et al (2020) Clinical development of immuno-oncology in China. Lancet Oncol 21(8):1013–1016. https://doi.org/10.1016/S1470-2045(20)30329-6CrossRef

18.

Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7CrossRef

19.

Yang S, Zhang W, Chen Q et al (2020) Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: a retrospective study. Cancer Manag Res 12:10333–10340. https://doi.org/10.2147/CMAR.S280096CrossRef

20.

Zhai C, Zhang X, Ren L et al (2021) The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer. Front Oncol 10:619010. https://doi.org/10.3389/fonc.2020.619010CrossRef

21.

Wang P, Fang X, Yin T et al (2021) Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol 11:628124. https://doi.org/10.3389/fonc.2021.628124CrossRef

22.

Jin R, Zhao J, Xia L et al (2020) Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Ther Adv Med Oncol 12:1758835920930333. https://doi.org/10.1177/1758835920930333CrossRef

23.

Guisier F, Cousse S, Jeanvoine M et al (2019) A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer. Sci Rep 9(1):16902. https://doi.org/10.1038/s41598-019-52913-zCrossRef

24.

Chardin D, Paquet M, Schiappa R et al (2020) Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer 8(2):e000645. https://doi.org/10.1136/jitc-2020-000645CrossRef

25.

Nishino M, Giobbie-Hurder A, Ramaiya NH et al (2014) Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2(1):40. https://doi.org/10.1186/s40425-014-0040-2CrossRef

26.

Colak S, Ten Dijke P (2017) Targeting TGF-β signaling in cancer. Trends Cancer 3(1):56–71. https://doi.org/10.1016/j.trecan.2016.11.008CrossRef

27.

Aggarwal C, Somaiah N, Simon G (2012) Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 13(5):247–263. https://doi.org/10.4161/cbt.19594CrossRef

28.

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. https://doi.org/10.1056/NEJMoa061884CrossRef

29.

Shen G, Zheng F, Ren D et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11(1):120. https://doi.org/10.1186/s13045-018-0664-7CrossRef

30.

Li J, Zhao X, Chen L et al (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529. https://doi.org/10.1186/1471-2407-10-529CrossRef

31.

Jin Y, Wei L, Jiang Q et al (2018) Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. Sci Rep 8(1):15837. https://doi.org/10.1038/s41598-018-34030-5CrossRef

32.

Greenberg JI, Shields DJ, Barillas SG et al (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223):809–813. https://doi.org/10.1038/nature07424CrossRef

33.

Xian X, Håkansson J, Ståhlberg A et al (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116(3):642–651. https://doi.org/10.1172/JCI25705CrossRef

34.

García-Román J, Zentella-Dehesa A (2013) Vascular permeability changes involved in tumor metastasis. Cancer Lett 335(2):259–269. https://doi.org/10.1016/j.canlet.2013.03.005CrossRef

35.

Heldin CH (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 11:97. https://doi.org/10.1186/1478-811X-11-97CrossRef

36.

Fuso Nerini I, Cesca M, Bizzaro F et al (2016) Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer 35(1):61. https://doi.org/10.1186/s40880-016-0123-1CrossRef

37.

Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622. https://doi.org/10.1016/j.ccell.2014.10.006CrossRef

38.

Fukumura D, Kloepper J, Amoozgar Z et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325–340. https://doi.org/10.1038/nrclinonc.2018.29CrossRef

39.

Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 7(28):2518–2527. https://doi.org/10.1200/JCO.19.00934CrossRef

40.

Borghaei H, Gettinger S, Vokes EE et al (2021) Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 39(7):723–733. https://doi.org/10.1200/JCO.20.01605CrossRef

41.

Xie C, Wan X, Quan H et al (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109(4):1207–1219. https://doi.org/10.1111/cas.13536CrossRef

42.

Tian S, Quan H, Xie C et al (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102(7):1374–1380. https://doi.org/10.1111/j.1349-7006.2011.01939.xCrossRef

43.

Lopes-Coelho F, Martins F, Pereira SA et al (2021) Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22(7):3765. https://doi.org/10.3390/ijms22073765CrossRef

44.

Dahlberg SE, Sandler AB, Brahmer JR et al (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28(6):949–954. https://doi.org/10.1200/JCO.2009.25.4482CrossRef

45.

Goodwin R, Ding K, Seymour L et al (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 21(11):2220–2226. https://doi.org/10.1093/annonc/mdq221CrossRef

46.

Ziche M, Morbidelli L, Choudhuri R et al (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99(11):2625–2634. https://doi.org/10.1172/JCI119451CrossRef

47.

Hood JD, Meininger CJ, Ziche M et al (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 74(3):H1054–H1058. https://doi.org/10.1152/ajpheart.1998.274.3.H1054CrossRef

48.

Bobik A (2005) The structural basis of hypertension: vascular remodelling, rarefaction and angiogenesis/arteriogenesis. J Hypertens 23(8):1473–1475. https://doi.org/10.1097/01.hjh.0000174970.56965.4fCrossRef

49.

Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795. https://doi.org/10.1038/sj.bjc.6603813CrossRef

Title: Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Authors: Yu Feng
Le Tang
Hongyu Wang
Yutao Liu
Sheng Yang
Lin Lin
Xingsheng Hu
Yuankai Shi
Publication date: 07-08-2022
Publisher: Springer Berlin Heidelberg
Keywords: Bevacizumab
Checkpoint Inhibitors
Published in: Cancer Immunology, Immunotherapy / Issue 2/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-022-03251-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2023

CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Single-cell analysis of peripheral CD8+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer

Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors

A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer